This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective comparative study with historical controls, which was conducted at the MAMC in Tacoma (WA), USA. The data were obtained from hospital records. Follow-up phone consultations were carried out at 48 hours and 5 days. The overall follow-up lasted 6 months. No loss to follow-up was reported.
Analysis of effectiveness
It appears that all the patients included in the initial study sample have been considered in the analysis of effectiveness. The outcome measures used were: the total and mean number of hospital days; the number of maternal and newborn hospital readmissions postpartum; the number of maternal and newborn unscheduled clinic visits; and the number of maternal and newborn emergency visits.
Patient satisfaction with the pathway was evaluated using a Likert visual scale with 17 pertinent questions. The score ranged from 1 (worst) to 5 (best). The authors did not discuss the baseline comparability of the study groups.
Effectiveness results
The average satisfaction score was 3.8, suggesting "excellent" satisfaction with the early discharge programme.
The total number of hospital days was 2,668 in the control group and 1,965 in the intervention group, (p<0.05). The mean numbers of hospital days were 2.56 (control) and 1.87 (intervention), respectively, (p<0.05).
There were 3 (0.2%) maternal hospital readmissions postpartum in the control group versus 7 (0.6%) in the intervention group. The odds ratio (OR) was 2.32 (95% confidence interval, CI: 2.17 -6.92; p<0.05). However, these admissions were not clinically significant because they were all for postpartum mastitis or endometritis, and they occurred after 48 hours of hospital discharge.
There were 9 newborn hospital readmissions in the control group versus 12 in the intervention group, (p>0.05).
The number of maternal unscheduled clinic visits was 123 in the control group and 237 in the intervention group, (p>0.05). The numbers of newborn unscheduled clinic visits were 106 (control) and 216 (intervention), respectively (OR 3.03, 95% CI: 2.18 -4.27; p<0.05).
The number of maternal emergency visits was 55 in the control group and 67 in the intervention group, (p>0.05). The number of newborn emergency visits was 42 in each group, (p>0.05).
Clinical conclusions
The effectiveness analysis showed that the new clinical pathway was effective in reducing the length of stay postpartum and was associated with high patient satisfaction. However, the numbers of maternal readmissions and newborn unscheduled clinic visits were significantly higher in comparison with standard care.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences study was carried out.
retrospectively. The main drawback of such a design was the fact that the two study groups were not studied concurrently and factors other than the implementation of the clinical pathway could have affected the results of the analysis. In fact, the authors did not demonstrate that other important changes in the management of uncomplicated vaginal delivery did not occur during the timeframe of the study. Moreover, the baseline comparability of the two groups of patients was not commented upon. The use of a fully prospective and randomised study would have been more appropriate. Power calculations were not performed to justify the size of the sample. The authors stated that a far larger group of patients should have been enrolled to show no change in maternal or newborn readmissions, as reported in an earlier study. The study sample was not selected on the basis of strict inclusion criteria, but it appears to have been representative of the study population. However, the effectiveness evidence came from a single military institution, which might limit the generalisability of the study results to other settings or medical centres.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-consequences analysis was conducted.
